Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...